Daré Bioscience (DARE)

Executive Summary

Daré Bioscience is a clinical-stage biotechnology company dedicated to developing innovative therapies for women's health, with a pipeline spanning non-hormonal contraception, menopause, and vaginal health. The company's lead candidate, DARE-001 (a non-hormonal contraceptive gel), is in Phase 2 clinical trials, while DARE-002 (for vaginal atrophy) is nearing the end of Phase 2. Daré's science-driven approach aims to address significant unmet needs in areas historically underfunded by pharma, positioning it as a potential leader in women's health. As of early 2026, the company is privately held but publicly traded under ticker DARE, with a valuation of approximately $40 million and 14.6 million shares outstanding. Daré's near-term milestones include top-line Phase 2 data readouts for DARE-001 and DARE-002, which could validate its platform and unlock value through partnerships or licensing. However, the company faces typical development risks, including regulatory hurdles and capital needs to fund later-stage trials. With a focused pipeline and growing awareness of women's health, Daré is poised to execute on its strategy. The conviction score reflects moderate confidence given the early-stage nature of its assets and the absence of approved products, balanced by the clear therapeutic need and potential for breakthrough data.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data for DARE-001 (non-hormonal contraceptive gel)50% success
• Q1 2027Initiation of Phase 3 trial for DARE-002 (vulvovaginal atrophy)70% success
• H2 2026Potential licensing or partnership deal for DARE-001 or DARE-00230% success